Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Oliver Sartor MD Advisory Board

David Henry MD Advisory Board

Benjamin O. Anderson MD, FACS Advisory Board

See All Experts

featured

Published in Oncology and

Expert Opinion / Interview · September 25, 2017

My Approach to Utilizing Molecular Markers in Prostate Cancer

Interview by

Farzanna S Haffizulla MD, FACP, FAMWA

Interview with

Oliver Sartor MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Oliver Sartor MD

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

featured

2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer

Commentary · December 06, 2022
featured

Impact of Salvage Radiotherapy Initiation at PSA ≤0.5 ng/mL on Survival Outcomes in Patients With Relapsed Prostate Cancer After Prostatectomy

Prostate · November 17, 2022
featured

Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations

Clin. Cancer Res · November 17, 2022
story of the week

PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Lancet Oncol · November 07, 2022
story of the week

Prostate Cancer Aggressiveness and Financial Toxicity in Patients With Prostate Cancer

Prostate · November 01, 2022
featured

VISION Trial Analysis of Time-to-Event Endpoints Associated With Radioligand Therapy

Interview · October 11, 2022
featured

Androgen Annihilation in Patients With High-Risk, Biochemically Relapsed Prostate Cancer

Interview · October 10, 2022
story of the week

Gene-Based Confirmatory Germline Testing Following Tumor-Only Sequencing of Prostate Cancer

Eur Urol · October 06, 2022

updated
featured

Duration of Androgen Deprivation Therapy With Post-Operative Radiotherapy for Prostate Cancer

Interview · October 05, 2022
featured

Abiraterone Plus Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer

Interview · October 04, 2022

Advanced Prostate Cancer

My Approach to Utilizing Molecular Markers in Prostate Cancer

Additional Info

Advanced Prostate Cancer Center of Excellence

2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer

Impact of Salvage Radiotherapy Initiation at PSA ≤0.5 ng/mL on Survival Outcomes in Patients With Relapsed Prostate Cancer After Prostatectomy

Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations

PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Aggressiveness and Financial Toxicity in Patients With Prostate Cancer

VISION Trial Analysis of Time-to-Event Endpoints Associated With Radioligand Therapy

Androgen Annihilation in Patients With High-Risk, Biochemically Relapsed Prostate Cancer

Gene-Based Confirmatory Germline Testing Following Tumor-Only Sequencing of Prostate Cancer

Duration of Androgen Deprivation Therapy With Post-Operative Radiotherapy for Prostate Cancer

Abiraterone Plus Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer

Further Reading

Stereotactic Body Radiotherapy for Localized Prostate Cancer

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Nivolumab Plus AVD for Advanced-Stage Classic Hodgkin's Lymphoma

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Ponsegromab for Treating Cancer Cachexia

Clinical Validation of a Tissue-Agnostic Genome-Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies

Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma

First-in-Human Study of MTA-Cooperative PRMT5 Inhibitor AMG 193 in Patients With MTAP-Deleted Solid Tumors

Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

Relationship Between Soluble IL-2 Receptor Levels and Prognosis in DLBCL

Related Videos